PTX Therapeutics PTX Therapeutics PTX Therapeutics
  • Toggle menu
    PTX Therapeutics PTX Therapeutics PTX Therapeutics
    • HOME
    • ABOUT US
    • TECHNOLOGIES
      • Our Technologies
      • PIPELINE
    • INVESTORS
      • Investor Centre
      • Live Investor Briefing
      • SHARE PRICE AND ANNOUNCEMENTS
      • Corporate Governance And Directory
    • MEDIA
      • Media
      • Briefing recordings
        • Q&A Update with Professor H. Miles Prince
    • CONTACT US

    Blog Post

    Home > News > Prescient Therapeutics Port Jackson Webinar

    Prescient Therapeutics Port Jackson Webinar

    March 29, 2023 AUTHOR – enouvoteam
    Article, News 0

     

    Tags In
    Port Jackson Securities
    Share
    246 / 305

    Related Posts

    Prescient Therapeutics and Carina Biotech to develop CAR-T cell solid tumour therapies

    News 0

    New T-Cell Lymphoma therapy coming soon

    Article, News 0

    Prescient Therapeutics bolsters scientific advisory board with CAR-T and bioengineering experts

    News 0
    STOCK PRICE
    ASX ANNOUNCEMENTS

    RECENT POSTS

    0
    Just the Facts: Prescient Therapeutics secures FDA approval for PTX-100 Phase 2 trials
    By enouvoteam
    0
    Prescient Therapeutics welcomes US FDA allowance of Investigational New Drug application for PTX-100 Phase 2 clinical trial
    By enouvoteam
    0
    Prescient Therapeutics appoints experienced pharmaceuticals executive James McDonnell as CEO
    By enouvoteam

    Categories

    • Article (106)
    • Media (13)
    • News (305)
    • Uncategorized (1)
    • Webcast Video (7)

    Tags

    AusBiz Biotech Dispatch BioWorld CGT Live Global Victoria Investing Kalkine Kalkine Media Market Herald Market Open Mirage News National Tribune Pitt Street Research Port Jackson Securities Prescient Therapeutics Proactive Investors Reach Markets ShareCafe Share Cafe Small Caps Smallcaps Stockhead Sub11 Switzer TechKnow Invest Roadshow The Australian The Australian Business Review The Market Herald The Sentiment Yahoo Finance
    Logo

    Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cell therapies.

    CONTACT

    P: +61 3 9692 7222

    F: +61 3 9077 9233

    E: [email protected]

    ABOUT

    TECHNOLOGIES

    PIPELINE

    INVESTORS

    Reach Logo

    This Investor Centre was built by Reach Markets.
    Visit Reach Markets here

    ©2025 REACH MARKETS

    Close

    Subscribe for updates




    What is a 708 investor?

    By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Corporate provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.

    ×

    Do you qualify as a Wholesale (708) investor?

    Wholesale 708 Sophisticated Investors are individuals or entities who generally qualify under Sections 708(8) and s761G(7) of the Corporations Act based on the gross income and/or net assets test verified by a qualified accountant.
    • A gross income of $250,000 or more per annum in each of the previous two financial years; or
    • Net assets of at least $2.5 million; and
    • A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)